Edwards Lifesciences Financial Statements (EW)
|
|
|
|
Report date
|
|
|
31.12.2022 |
13.02.2023 |
12.02.2024 |
28.02.2025 |
25.02.2026 |
|
25.02.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
5 382 |
5 382 |
5 010 |
5 440 |
6 068 |
|
6 068 |
|
Operating Income, bln rub |
|
|
1 749 |
1 702 |
1 427 |
1 379 |
1 636 |
|
1 621 |
|
EBITDA, bln rub |
? |
|
1 784 |
1 960 |
1 535 |
1 723 |
1 430 |
|
1 391 |
|
Net profit, bln rub |
? |
|
1 522 |
1 522 |
1 402 |
4 175 |
1 074 |
|
1 070 |
|
|
OCF, bln rub |
? |
|
|
1 218 |
895.8 |
542.3 |
1 595 |
|
1 595 |
|
CAPEX, bln rub |
? |
|
|
264.8 |
266.3 |
252.4 |
260.2 |
|
260.2 |
|
FCF, bln rub |
? |
|
|
953.4 |
629.5 |
289.9 |
1 335 |
|
1 335 |
|
Dividend payout, bln rub
|
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
2 513 |
2 513 |
2 545 |
2 943 |
3 105 |
|
3 118 |
|
Cost of production, bln rub |
|
|
1 080 |
1 167 |
1 037 |
1 118 |
1 327 |
|
1 330 |
|
R&D, bln rub |
|
|
945.2 |
945.2 |
962.9 |
1 053 |
1 079 |
|
1 079 |
|
Interest expenses, bln rub |
|
|
16.3 |
26.2 |
17.6 |
19.8 |
0.000 |
|
0.000 |
|
|
Assets, bln rub |
|
|
8 293 |
8 293 |
9 363 |
13 055 |
13 697 |
|
13 697 |
|
Net Assets, bln rub |
? |
|
5 807 |
5 807 |
6 650 |
9 998 |
10 338 |
|
10 338 |
|
Debt, bln rub |
|
|
691.3 |
691.3 |
685.1 |
700.0 |
705.4 |
|
705.4 |
|
Cash, bln rub |
|
|
1 215 |
1 215 |
1 633 |
3 976 |
4 227 |
|
4 227 |
|
Net debt, bln rub |
|
|
-524.0 |
-524.0 |
-947.7 |
-3 276 |
-3 521 |
|
-3 521 |
|
|
Ordinary share price, rub |
|
|
74.6 |
74.6 |
76.3 |
74.0 |
85.3 |
|
83.2 |
|
Number of ordinary shares, mln |
|
|
619.0 |
619.0 |
606.7 |
597.7 |
584.8 |
|
580.4 |
|
|
Market cap, bln rub |
|
|
46 184 |
46 184 |
46 261 |
44 248 |
49 854 |
|
48 278 |
|
EV, bln rub |
? |
|
45 660 |
45 660 |
45 313 |
40 972 |
46 333 |
|
44 756 |
|
Book value, bln rub |
|
|
4 357 |
4 357 |
5 106 |
7 045 |
7 441 |
|
7 441 |
|
|
EPS, rub |
? |
|
2.46 |
2.46 |
2.31 |
6.98 |
1.84 |
|
1.84 |
|
FCF/share, rub |
|
|
0.00 |
1.54 |
1.04 |
0.49 |
2.28 |
|
2.30 |
|
BV/share, rub |
|
|
7.04 |
7.04 |
8.42 |
11.8 |
12.7 |
|
12.8 |
|
|
EBITDA margin, % |
? |
|
33.1% |
36.4% |
30.6% |
31.7% |
23.6% |
|
22.9% |
|
Net margin, % |
? |
|
28.3% |
28.3% |
28.0% |
76.7% |
17.7% |
|
17.6% |
|
FCF yield, % |
? |
|
0.00% |
2.06% |
1.36% |
0.66% |
2.68% |
|
2.77% |
|
ROE, % |
? |
|
26.2% |
26.2% |
21.1% |
41.8% |
10.4% |
|
10.4% |
|
ROA, % |
? |
|
18.4% |
18.4% |
15.0% |
32.0% |
7.84% |
|
7.81% |
|
|
P/E |
? |
|
30.3 |
30.3 |
33.0 |
10.6 |
46.4 |
|
45.1 |
|
P/FCF |
|
|
|
48.4 |
73.5 |
152.6 |
37.3 |
|
36.2 |
|
P/S |
? |
|
8.58 |
8.58 |
9.23 |
8.13 |
8.22 |
|
7.96 |
|
P/BV |
? |
|
10.6 |
10.6 |
9.06 |
6.28 |
6.70 |
|
6.49 |
|
EV/EBITDA |
? |
|
25.6 |
23.3 |
29.5 |
23.8 |
32.4 |
|
32.2 |
|
Debt/EBITDA |
|
|
-0.29 |
-0.27 |
-0.62 |
-1.90 |
-2.46 |
|
-2.53 |
|
|
R&D/CAPEX, % |
|
|
|
356.9% |
361.6% |
417.2% |
414.8% |
|
414.8% |
|
|
CAPEX/Revenue, % |
|
|
0.00% |
4.92% |
5.32% |
4.64% |
4.29% |
|
4.29% |
|
| Edwards Lifesciences shareholders |
